RELAY THERAPEUTICS INC (RLAY) Stock Price, Quote, News and Overview
NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD
RLAY Quote, Performance and Key Statistics
3.92
-0.17 (-4.16%)
The current stock price of RLAY is 3.92 USD. In the past month the price decreased by -19.84%. In the past year, price decreased by -60.8%.
RLAY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RLAY
Company Profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is headquartered in Cambridge, Massachusetts and currently employs 294 full-time employees. The company went IPO on 2020-07-16. The firm is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Company Info
RELAY THERAPEUTICS INC
399 Binney Street, 2nd Floor
Cambridge MASSACHUSETTS 02139 US
CEO: Sanjiv K. Patel
Employees: 304
Company Website: https://relaytx.com/
Investor Relations: https://ir.relaytx.com/
Phone: 16173708837
RELAY THERAPEUTICS INC / RLAY FAQ
What is the stock price of RELAY THERAPEUTICS INC today?
The current stock price of RLAY is 3.92 USD. The price decreased by -4.16% in the last trading session.
What is the ticker symbol for RELAY THERAPEUTICS INC stock?
The exchange symbol of RELAY THERAPEUTICS INC is RLAY and it is listed on the Nasdaq exchange.
On which exchange is RLAY stock listed?
RLAY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RELAY THERAPEUTICS INC stock?
19 analysts have analysed RLAY and the average price target is 21.93 USD. This implies a price increase of 459.44% is expected in the next year compared to the current price of 3.92. Check the RELAY THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RELAY THERAPEUTICS INC worth?
RELAY THERAPEUTICS INC (RLAY) has a market capitalization of 656.13M USD. This makes RLAY a Small Cap stock.
How many employees does RELAY THERAPEUTICS INC have?
RELAY THERAPEUTICS INC (RLAY) currently has 304 employees.
What are the support and resistance levels for RELAY THERAPEUTICS INC (RLAY) stock?
RELAY THERAPEUTICS INC (RLAY) has a support level at 3.73 and a resistance level at 4.17. Check the full technical report for a detailed analysis of RLAY support and resistance levels.
Is RELAY THERAPEUTICS INC (RLAY) expected to grow?
The Revenue of RELAY THERAPEUTICS INC (RLAY) is expected to decline by -39.68% in the next year. Check the estimates tab for more information on the RLAY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RELAY THERAPEUTICS INC (RLAY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RLAY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RLAY, evaluating the profitability, health, valuation and growth aspects
- RELAY THERAPEUTICS INC (RLAY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RELAY THERAPEUTICS INC (RLAY) Sales and EPS estimates to see what analysts future expectations are.
- RELAY THERAPEUTICS INC (RLAY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RELAY THERAPEUTICS INC (RLAY) Insider and Institutional Ownership to learn about the owners and their transactions.
- RELAY THERAPEUTICS INC (RLAY) Stock Chart to make your own analysis
- RELAY THERAPEUTICS INC (RLAY) Latest news and press-releases to stay up to date.
Does RELAY THERAPEUTICS INC (RLAY) stock pay dividends?
RLAY does not pay a dividend.
When does RELAY THERAPEUTICS INC (RLAY) report earnings?
RELAY THERAPEUTICS INC (RLAY) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of RELAY THERAPEUTICS INC (RLAY)?
RELAY THERAPEUTICS INC (RLAY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.61).
What is the Short Interest ratio of RELAY THERAPEUTICS INC (RLAY) stock?
The outstanding short interest for RELAY THERAPEUTICS INC (RLAY) is 11.6% of its float. Check the ownership tab for more information on the RLAY short interest.
RLAY Technical Analysis
RLAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLAY. RLAY has a great financial health rating, but its profitability evaluates not so good.
RLAY Financial Highlights
Over the last trailing twelve months RLAY reported a non-GAAP Earnings per Share(EPS) of -2.61. The EPS increased by 2.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.9% | ||
| ROE | -71.96% | ||
| Debt/Equity | 0 |
RLAY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to RLAY. The Buy consensus is the average rating of analysts ratings from 19 analysts.
For the next year, analysts expect an EPS growth of 8.27% and a revenue growth -39.68% for RLAY